510(k) Report

510(k) · Cleared

Cleared

Hema Screen Specific Ifobt

K060463510(k) TraditionalCleared Jun 6, 2006104-day reviewClass II21 CFR 864.6550

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Immunostics Inc., · KHE Reagent, Occult Blood

Cleared on Jun 6, 2006 after a 104-day review. FDA’s file for it is a 510(k) statement, which names no predicate. 1 later device descends from it.

Decided
Jun 6, 2006
Review
104 days
Class
Class II
Product code
KHE
Recalls
None
Predicates
0

1 later device descends from it, 1 citing it directly.

Descendants, by year cleared 2017: 1 descendant cleared20052010201520202025
  1. This deviceK060463 Hema Screen Specific IfobtImmunostics Inc., · 2006
  2. Descendant · cites it directly · 0 of its ownK171484 hema-screen SPECIFIC GoldImmunostics Inc., · 2017

Most influential descendants

Showing 1 of 1 · See all
  • K171484hema-screen SPECIFIC GoldImmunostics Inc., · 2017 · cites it directly0descendants
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
0 (this device)K060463Hema Screen Specific IfobtImmunostics Inc.,2006—
+1K171484hema-screen SPECIFIC GoldImmunostics Inc.,2017—

Descendants by year cleared

Year clearedDevicesWith a Class I recall
201710
FIG. 1 — Lineage of K060463, 2006–2017Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA 510(k) statement (indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in KHE? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

  • Candidate predicates for a device like this, rankedin the report
  • Recall history across each candidate’s familyin the report
Get a 510(k) Report

What was it cleared against?

FDA’s file for it is a 510(k) statement, which names no predicate.

What descends from it? (1)

1 later device cites it directly; ranked here by how many devices descend from each in turn.

NumberDeviceApplicantDecidedDescendants
K171484hema-screen SPECIFIC GoldImmunostics Inc.,20170

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • Of its descendants, K171484 (Immunostics Inc.,, 2017) has gone furthest, with 0 descendants of its own.

How does its category compare?

All KHE devices

KHE Reagent, Occult Blood: FDA decisions, review times, recalls and adverse event reports over 20 years.

FDA decisions per year · KHE

1in 2018

2007: 32008: 32010: 22011: 22012: 22015: 12017: 42018: 1
2007high 4 (2017) · low 0 (2009)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · KHE

126in 2017

2007: 104 days median2008: 93 days median2017: 126 days median
2007high 126 (2017) · low 93 (2008)2026

Receipt to decision; years with fewer than 3 clearances left blank.

Recalls per year · KHE

2in 2025

2008: 12011: 62013: 22018: 12020: 12025: 2
2007high 6 (2011) · low 0 (2007)2026

Class I (0 since 2007) Class II/III not classified

Adverse event reports per year · KHE

3in 2025

2007: 32008: 52009: 52010: 42011: 42012: 32013: 162014: 62015: 102016: 32017: 12018: 12019: 12020: 12021: 22023: 12024: 22025: 3
2007high 16 (2013) · low 0 (2022)2025

MAUDE reports naming product code KHE, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
2007310403
200839315
20090—05
20102—04
20112—64
20122—03
20130—216
20140—06
20151—010
20160—03
2017412601
20181—11
20190—01
20200—11
20210—02
20220—00
20230—01
20240—02
20250—23
20260—0—

What is it indicated for?

The Hema-ScreenT M Specific is for the rapid and qualitative determination of Human Blood fecal samples. It is intended for professional and laboratory use only. It is also useful for determining gastrointestinal bleeding due to a number of gastrointestinal (G I) disorders such as diverticulitis, colitis, polyps and colorectal cancer. This test is recommended for use in routine physical examines, hospital monitoring of bleeding in patients, and for screening for colorectal cancer or gastrointestinal (GI) bleeding from any source.

Indications for use as stated in the FDA 510(k) statement.

Cite this page

510(k) Report. “K060463: Hema Screen Specific Ifobt.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K060463

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026